



## Cadila Healthcare Limited

Registered Office: Zydus Tower, Satellite Cross Roads, Ahmedabad - 380015  
Tel. No.: (+91-79) 2686 8100 Fax No.: (+91-79) 2686 2365/66 Website: www.zyduscadila.com  
CIN : L24230GJ1995PLC025878

### PART I

#### Statement of Results for the Quarter Ended 30/06/2014

Rupees in Lacs				Sr. No.	Particulars	Rupees in Lacs			
CONSOLIDATED						COMPANY			
3 Months ended 30/06/2014 (Unaudited)	Preceding 3 months ended 31/03/2014 (Audited)	Corresponding 3 months ended 30/06/2013 in the previous year (Unaudited)	Previous year ended 31/03/2014 (Audited)			3 Months ended 30/06/2014 (Unaudited)	Preceding 3 months ended 31/03/2014 (Audited)	Corresponding 3 months ended 30/06/2013 in the previous year (Unaudited)	Previous year ended 31/03/2014 (Audited)
<b>205,680</b>	195,198	164,633	720,834	1	<b>Income from operations</b>	<b>100,372</b>	100,478	81,234	358,733
<b>3,642</b>	3,565	3,888	14,827	i	Gross Sales	<b>1,681</b>	1,436	1,532	6,280
<b>202,038</b>	191,633	160,745	706,007	ii	Less: Excise Duty	<b>98,691</b>	99,042	79,702	352,453
<b>2,974</b>	5,217	2,960	16,396	a	Net Sales	<b>12,588</b>	11,112	13,108	51,758
<b>205,012</b>	196,850	163,705	722,403	b	Other operating income	<b>111,279</b>	110,154	92,810	404,211
<b>47,053</b>	41,956	38,613	162,882	c	Total income from operations (net)	<b>31,655</b>	26,673	24,864	106,814
<b>40,624</b>	33,620	21,062	115,430	2	<b>Expenses</b>	<b>11,537</b>	10,580	8,920	38,266
<b>(6,345)</b>	2,187	(5,736)	(6,949)	a	Cost of materials consumed	<b>(5,189)</b>	32	(2,422)	(3,571)
<b>29,013</b>	27,357	26,310	107,111	b	Purchases of stock-in-trade	<b>15,176</b>	13,303	13,409	52,514
<b>6,770</b>	5,278	4,712	20,123	c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	<b>5,295</b>	3,217	3,039	12,740
<b>57,056</b>	55,875	54,877	223,915	d	Employee benefits expense	<b>31,715</b>	32,079	30,473	129,489
<b>174,171</b>	166,273	139,838	622,512	e	Depreciation and amortisation expense	<b>90,189</b>	85,884	78,283	336,252
<b>30,841</b>	30,577	23,867	99,891	f	Other expenses	<b>21,090</b>	24,270	14,527	67,959
<b>1,041</b>	1,313	1,253	5,067	g	Total expenses	<b>1,634</b>	2,035	21,954	30,859
<b>31,882</b>	31,890	25,120	104,958	3	<b>Profit/ (Loss) from Operations before other income, finance costs and exceptional items (1-2)</b>	<b>22,724</b>	26,305	36,481	98,818
<b>1,808</b>	2,404	2,784	9,019	4	Other income	<b>825</b>	1,001	1,460	4,251
<b>30,074</b>	29,486	22,336	95,939	5	<b>Profit/ (Loss) from ordinary activities before finance costs and exceptional items (3+4)</b>	<b>21,899</b>	25,304	35,021	94,567
<b>118</b>	1,368	0	1,715	6	Finance costs	<b>0</b>	0	0	0
<b>29,956</b>	28,118	22,336	94,224	7	<b>Profit/ (Loss) from ordinary activities after finance costs but before exceptional items (5-6)</b>	<b>21,899</b>	25,304	35,021	94,567
<b>5,244</b>	3,476	2,031	10,601	8	Exceptional items	<b>2,170</b>	3,636	999	4,208
<b>24,712</b>	24,642	20,305	83,623	9	<b>Profit/ (Loss) from ordinary activities before tax (7-8)</b>	<b>19,729</b>	21,668	34,022	90,359
<b>0</b>	0	0	0	10	Tax expense	<b>0</b>	0	0	0
<b>24,712</b>	24,642	20,305	83,623	11	<b>Net Profit/ (Loss) from ordinary activities after tax (9-10)</b>	<b>19,729</b>	21,668	34,022	90,359
<b>0</b>	0	0	0	12	Extraordinary items (net of tax expense)	<b>0</b>	0	0	0
<b>24,712</b>	24,642	20,305	83,623	13	<b>Net Profit/ (Loss) for the period (11-12)</b>	<b>19,729</b>	21,668	34,022	90,359
<b>0</b>	0	0	0	14	Share of profit/ (loss) of associates	<b>0</b>	0	0	0
<b>(691)</b>	(723)	(799)	(3,264)	15	Minority interest	<b>0</b>	0	0	0
<b>24,021</b>	23,919	19,506	80,359	16	<b>Net Profit/ (Loss) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)</b>	<b>19,729</b>	21,668	34,022	90,359
<b>10,237</b>	10,237	10,237	10,237	17	Paid-up equity share capital (Face Value Rs. 5/-)	<b>10,237</b>	10,237	10,237	10,237
<b>333,662</b>	333,662	333,662	333,662	18	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	<b>333,662</b>	333,662	333,662	333,662
<b>11.73</b>	11.68	9.53	39.25	19 i	<b>Earnings per share (before extraordinary items)</b> <b>(of Rs. 5/- each) (not annualised):</b>	<b>9.64</b>	10.58	16.62	44.13
<b>11.73</b>	11.68	9.53	39.25	a	Basic (Rs.)	<b>9.64</b>	10.58	16.62	44.13
<b>11.73</b>	11.68	9.53	39.25	b	Diluted (Rs.)	<b>9.64</b>	10.58	16.62	44.13
<b>11.73</b>	11.68	9.53	39.25	19 ii	<b>Earnings per share (after extraordinary items)</b> <b>(of Rs. 5/- each) (not annualised):</b>	<b>9.64</b>	10.58	16.62	44.13
<b>11.73</b>	11.68	9.53	39.25	a	Basic (Rs.)	<b>9.64</b>	10.58	16.62	44.13
<b>11.73</b>	11.68	9.53	39.25	b	Diluted (Rs.)	<b>9.64</b>	10.58	16.62	44.13

#### Notes :

- [1] The above results for the quarter ended on June 30, 2014 were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on July 30, 2014.
- [2] The Statutory Auditors of the Company have carried out a "Limited Review" of the above results as per clause 41 of the Listing Agreement.
- [3] Effective from April 1, 2014, the Company has changed the depreciation charge based on the revised remaining useful lives of the assets as per the requirement of Schedule II of the Companies Act, 2013. Due to this, the depreciation charge for the quarter ended June 30, 2014 is higher by Rs. 1,613 Lacs on Standalone basis [Rs. 1,838 Lacs on Consolidated basis]. Further, based on transitional provision provided in Note 7(b) of Schedule II, an amount of Rs. 2,497 Lacs on Standalone basis [Rs.2,594 Lacs on Consolidated basis], which pertains to the carrying value of the assets whose remaining useful life as on April 1, 2014 is "Nil", has been adjusted to the Retained Earnings.
- [4] The Company has incorporated Zydus Discovery DMCC as a wholly owned subsidiary in Dubai on June 15, 2014.
- [5] The changes in investments during the quarter are as under:  
Zydus Worldwide DMCC [initial investments] - Rs. 8 Lacs  
Zydus Healthcare Philippines Inc. [additional investments] - Rs. 26 Lacs  
Zydus International Private Limited [additional investments] - Rs. 4,633 Lacs
- [6] Figures of previous reporting periods have been regrouped/ reclassified wherever necessary to correspond with the figures of the current reporting period.
- [7] The Company has one segment of activity viz., "Pharmaceuticals".

